Pulmonary Arterial Hypertension Clinical Trial
Official title:
Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension
The purpose of this study is to determine the prognostic value of echocardiographic
parameters in comparison with clinical and hemodynamic parameters in pulmonary arterial
hypertension (PAH).
A secondary purpose of this study is to analyze the disease evolution after 3 to 6 months.
In pulmonary fibrosis it has been demonstrated that the variation of clinical and
paraclinical parameters between 2 examinations has a prognostic interest. In this study the
prognostic value of variation of some echocardiographic parameters between initial
examination and echocardiography after 3 or 6 months will be evaluated.
Another secondary purpose is to create a common database for Pneumology, Cardiology and
Epidemiology departments with prospective registration of new cases of PAH and follow of
patients under treatment.
Pulmonary arterial hypertension (PAH) is a rare pathology with a poor prognosis and a median
survival lower than 3 years in the absence of a specific treatment.
The prognostic evaluation is based on clinical and hemodynamic data needing the right
cardiac catheterization. It has been shown that prognosis depends essentially on the
severity of right ventricular dysfunction. Recently, various echocardiographic parameters
derived from new techniques such as tissue Doppler have been validated for the evaluation of
right ventricular function. Some have been used as prognostic factor in cardiac
insufficiency, but not in PAH.
This is an observational retrospective and then prospective study. Usual PAH assessment
includes a complete clinical and paraclinical evaluation. History and physical examination
assess dyspnea, search signs of disease severity and quantify functional impact of 6
min-walking test. An echocardiography and a right cardiac catheterization are realized in
all patients. Clinical consultations of patients and control echocardiographic and
hemodynamic examinations are programmed at regular intervals.
The demonstration of prognostic value of some echocardiographic parameters could diminish
right cardiac catheterizations.
;
Observational Model: Cohort
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04076241 -
Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension
|
N/A | |
| Completed |
NCT05521113 -
Home-based Pulmonary Rehabilitation With Remote Monitoring in Pulmonary Arterial Hypertension
|
||
| Recruiting |
NCT04972656 -
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
|
N/A | |
| Completed |
NCT04908397 -
Carnitine Consumption and Augmentation in Pulmonary Arterial Hypertension
|
Phase 1 | |
| Active, not recruiting |
NCT03288025 -
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
|
N/A | |
| Completed |
NCT01959815 -
Novel Screening Strategies for Scleroderma PAH
|
||
| Recruiting |
NCT04266197 -
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
|
Phase 2 | |
| Active, not recruiting |
NCT06092424 -
High Altitude (HA) Residents With Pulmonary Vascular Diseseases (PVD), Pulmonary Artery Pressure (PAP) Assessed at HA (2840m) vs Sea Level (LA)
|
N/A | |
| Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
| Terminated |
NCT02060487 -
Effects of Oral Sildenafil on Mortality in Adults With PAH
|
Phase 4 | |
| Terminated |
NCT02253394 -
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
|
Phase 4 | |
| Withdrawn |
NCT02958358 -
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
|
N/A | |
| Terminated |
NCT01953965 -
Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.
|
Phase 2 | |
| Not yet recruiting |
NCT01649739 -
Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost
|
Phase 4 | |
| Withdrawn |
NCT01723371 -
Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children
|
Phase 1/Phase 2 | |
| Unknown status |
NCT01712997 -
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
|
Phase 3 | |
| Completed |
NCT01548950 -
Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
|
N/A | |
| Completed |
NCT01165047 -
Nitric Oxide, GeNO Nitrosyl Delivery System
|
Phase 2 | |
| Completed |
NCT00942708 -
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
|
Phase 2 | |
| Completed |
NCT00963027 -
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
|
Phase 1 |